GenSight Biologics Issues Warrants in EUR 1 Million Fundraising

GenSight Biologics completed its EUR 1 million fundraising, announced October 8, 2026, issuing shares and warrants. The issuance included 11,940,300 pre-funded warrants exercisable for 11,940,300 additional ordinary shares. A further 14,537,704 investor warrants carry rights to subscribe for 7,268,852 additional ordinary shares. The fundraising also issued 2,597,404 ordinary shares, admitted to trading on Euronext Paris on October 12, 2026. Neither the pre-funded warrants nor the investor warrants will be admitted to trading on any exchange. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gensight Biologics SA published the original content used to generate this news brief via (Ref. ID: 20261016282856) on October 16, 2026, and is solely responsible for the information contained therein. (C)